Drug intelligence / Profile preview

pilavapadin

Development stage: Phase 2
Lead developer: Lexicon Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Pilavapadin is an investigational, non-opioid, small molecule inhibitor of adaptor-associated kinase 1 (AAK1), designed for treating neuropathic pain. It is orally administered once daily and has shown promise in reducing diabetic peripheral neuropathic pain (DPNP) without affecting opiate pathways. Developed by Lexicon Pharmaceuticals, it has received Fast Track designation from the FDA for DPNP.

Other names: LX-9211LX9211LX 9211

Targets

AAK1 (Adaptor-associated kinase 1)

Beyond the preview

Go deeper on pilavapadin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pilavapadin.

Explore the full profile